



Turning Point Therapeutics Mourns the Death of Board Member Lewis Shuster

SAN DIEGO, December 17, 2018 – Athena Countouriotis, M.D., chief executive officer of Turning Point Therapeutics, Inc., issued the following statement on behalf of the company’s board and employees regarding the death of board member Lewis Shuster.

“We are deeply saddened by the loss of one of San Diego’s great biotech leaders, who was a mentor and friend to all who had the good fortune to know or work with him,” said Dr. Countouriotis. “Lew brought passion and commitment to his work, operated with great humility and integrity, and generously shared his deep experience from 30 years in strategic, financial and operational leadership roles. Lew’s passing from a very short battle with late-stage pancreatic cancer motivates our team even more now. Our thoughts are with Lew’s wife and family for their immeasurable loss.”

Mr. Shuster served as CEO, CFO and COO of life science companies including Kemia, Invitrogen, Pharmacopeia and Human Genome Sciences, and as a director of more than a dozen life science companies. In addition to his role on the Turning Point Therapeutics board, he served as a Director of HTG Molecular Diagnostics, Principia Biopharma, Cleave Biosciences, and Active Motif.

About Turning Point Therapeutics Inc.

Turning Point Therapeutics is a clinical-stage precision oncology company forging a new path for targeted cancer care. Founded in October 2013 by Dr. J. Jean Cui, the lead inventor of Pfizer’s oncology drugs crizotinib and lorlatinib, the company is developing a pipeline of novel drugs that aim to tackle treatment resistance and give new hope to patients who have stopped responding to available targeted therapies. Mounting clinical data for the company’s lead program, repotrectinib, a next-generation kinase inhibitor targeting genetic drivers of non-small cell lung cancer and advanced solid tumors, has shown ongoing antitumor activity and durable responses among treatment-naïve and pre-treated patients. With additional programs underway to address similarly intractable oncogenic drivers, Turning Point Therapeutics is marking a turning point in the way solid-tumor cancers are treated. For more information, visit www.tptherapeutics.com.

###